文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

肾素-血管紧张素系统通路治疗与男性COVID-19住院患者预后改善相关

Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19.
PubMed 文献 · Crit Care Med · 2022-05-18
一句话结论男性和女性COVID-19住院患者对ARB的反应存在性别差异:入院前使用ARB与男性机械通气及血管加压药使用减少相关,女性无此效应。

ARBs CORONA I是一项加拿大10家大都市医院的多中心前瞻性观察性队列研究,纳入1686例PCR确诊的急性COVID-19住院患者(2020年2月至2021年3月)。比较入院前使用ARB或ACE抑制剂与未使用者,按性别分层分析。男性入院前使用ARB者机械通气使用减少(aOR=0.52,p=0.007)、血管加压药使用减少(aOR=0.55,p=0.011),女性无显著效应;交互作用检验在机械通气(p=0.006)和血管加压药(p=0.044)上显著。亚组46例检测RAS组分,男性基线ACE-1及第7、14天血管紧张素II显著高于女性。提示RAS失调的性别差异可能解释COVID-19结局及ARB反应差异。

要点

  • 男性COVID-19住院患者入院前使用ARB与机械通气使用减少相关(aOR=0.52,p=0.007)。
  • 男性入院前使用ARB与血管加压药使用减少相关(aOR=0.55,p=0.011)。
  • 女性中未观察到ARB或ACE抑制剂对机械通气或血管加压药使用的显著效应。
  • 性别与ARB的交互作用在机械通气(p=0.006)和血管加压药(p=0.044)上显著。

适用人群与场景

  • PCR确诊的急性COVID-19住院成人患者,来自加拿大10家大都市医院(2020年2月至2021年3月)。
  • 分析比较入院前使用ARB或ACE抑制剂者与未使用者,按男性与女性分层。

研究设计与关键结果

  • 研究设计:前瞻性观察性队列研究,比较ARB或ACE抑制剂与未使用者在男性和女性中的效应。
  • 样本量:1686例PCR确诊COVID-19住院患者;亚组46例检测RAS组分,967例记录D-二聚体。
  • 男性入院前使用ARB者机械通气使用减少(aOR=0.52;p=0.007),血管加压药使用减少(aOR=0.55;p=0.011),对照为未使用ARB或ACE抑制剂者。
  • 女性中上述结局未观察到显著效应。
  • 交互作用检验:机械通气p=0.006,血管加压药p=0.044,提示ARB反应存在显著性别差异。
  • 男性基线血浆ACE-1及第7天、第14天血管紧张素II显著高于女性。

证据类型、等级与局限

  • 证据类型:前瞻性观察性多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,RAS失调的性别差异可能 contribute 于COVID-19结局及ARB反应的性别差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To determine whether angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors are associated with improved outcomes in hospitalized patients with COVID-19 according to sex and to report sex-related differences in renin-angiotensin system (RAS) components.

DESIGN: Prospective observational cohort study comparing the effects of ARB or ACE inhibitors versus no ARBs or ACE inhibitors in males versus females. Severe acute respiratory syndrome coronavirus 2 downregulates ACE-2, potentially increasing angiotensin II (a pro-inflammatory vasoconstrictor). Sex-based differences in RAS dysregulation may explain sex-based differences in responses to ARBs because the ACE2 gene is on the X chromosome. We recorded baseline characteristics, comorbidities, prehospital ARBs or ACE inhibitor treatment, use of organ support and mortality, and measured RAS components at admission and days 2, 4, 7, and 14 in a subgroup ( n = 46), recorded d -dimer ( n = 967), comparing males with females.

SETTING: ARBs CORONA I is a multicenter Canadian observational cohort of patients hospitalized with acute COVID-19. This analysis includes patients admitted to 10 large urban hospitals across the four most populated provinces.

PATIENTS: One-thousand six-hundred eighty-six patients with polymerase chain reaction-confirmed COVID-19 (February 2020 to March 2021) for acute COVID-19 illness were included.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Males on ARBs before admission had decreased use of ventilation (adjusted odds ratio [aOR] = 0.52; p = 0.007) and vasopressors (aOR = 0.55; p = 0.011) compared with males not on ARBs or ACE inhibitors. No significant effects were observed in females for these outcomes. The test for interaction was significant for use of ventilation ( p = 0.006) and vasopressors ( p = 0.044) indicating significantly different responses to ARBs according to sex. Males had significantly higher plasma ACE-1 at baseline and angiotensin II at day 7 and 14 than females.

CONCLUSIONS: ARBs use was associated with less ventilation and vasopressors in males but not females. Sex-based differences in RAS dysregulation may contribute to sex-based differences in outcomes and responses to ARBs in COVID-19.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Rocheleau GLY, Lee T, Mohammed Y, et al. Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19. Crit Care Med. 2022. PMID: 35607951. doi:10.1097/CCM.0000000000005589

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。